Trial · NCT06030193
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
NCT06030193, Phase 2, Completed, Qlaris Bio, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG). Trials, record NCT06030193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06030193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
- NCT number
- NCT06030193
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 37 participants, actual
- Lead sponsor
- Qlaris Bio, Inc.
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Interventions
- QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- First posted
- 2023-09-08
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of ocular symptoms and ocular treatment-emergent adverse events (TEAEs) | 14 days | Ocular safety and tolerability: (AEs) |
| Primary | Clinically significant change in visual acuity | 14 days | Ocular safety and tolerability: visual acuity |
| Primary | Clinically significant change in findings on slit lamp exam | 14 days | Ocular safety and tolerability: dilated biomicroscopy of eye to observe clinically significant changes from baseline |
| Primary | Clinically significant change in findings on fundus exam | 14 days | Ocular safety and tolerability: dilated ophthalmoscopy to observe clinically significant changes from baseline in posterior segment of eye |
| Primary | Incidence of systemic TEAEs | 14 days | Systemic safety and tolerability: AEs |
| Primary | Clinically significant changes in blood pressure (BP) | 14 days | Systemic safety and tolerability: vital sign, measuring systolic and diastolic blood pressure |
| Primary | Clinically significant changes in heart rate (HR) | 14 days | Systemic safety and tolerability: vital signs |
| Secondary | Change from baseline (CFB) of diurnal intraocular pressure (IOP) in the study eye | 14 days | Ocular hypotensive efficacy: diurnal IOP CFB |
| Secondary | CFB in IOP at various timepoints in the study eye | 14 days | Ocular hypotensive efficacy: IOP CFB for multiple timepoints throughout the day |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06030193
GET https://conductscience.org/api/trials/v1/NCT06030193/registered